Research reveals ecDNA's role in cancer growth; new drug BBI-2779 shows promise in treatment.

Recent research published in a scientific journal explores extrachromosomal DNA (ecDNA) and its role in cancer progression and treatment resistance. EcDNA contributes to tumor growth and can hinder treatment effectiveness. A new oral drug, BBI-2779, shows promise in shrinking tumors and preventing resistance in mice. Additionally, CHK1 inhibitors may selectively target tumor cells with ecDNA, offering potential new treatment options for aggressive cancers like breast, brain, and lung cancer.

November 06, 2024
10 Articles